iTeos Therapeutics (NASDAQ:ITOS - Get Free Report) is expected to announce its earnings results before the market opens on Wednesday, March 5th. Analysts expect the company to announce earnings of ($1.14) per share for the quarter.
iTeos Therapeutics Trading Up 3.7 %
NASDAQ:ITOS traded up $0.26 during trading hours on Friday, hitting $7.26. The company's stock had a trading volume of 644,749 shares, compared to its average volume of 273,999. The stock has a market capitalization of $265.24 million, a P/E ratio of -2.30 and a beta of 1.38. The stock has a fifty day moving average of $7.56 and a 200-day moving average of $9.76. iTeos Therapeutics has a 52-week low of $6.93 and a 52-week high of $18.75.
Analysts Set New Price Targets
Several equities analysts have issued reports on ITOS shares. Wells Fargo & Company dropped their price objective on iTeos Therapeutics from $31.00 to $19.00 and set an "overweight" rating on the stock in a report on Thursday, December 19th. Wedbush reaffirmed an "outperform" rating and set a $25.00 price objective on shares of iTeos Therapeutics in a report on Friday, January 10th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $21.00 price objective on shares of iTeos Therapeutics in a report on Thursday, January 16th.
Check Out Our Latest Stock Analysis on ITOS
iTeos Therapeutics Company Profile
(
Get Free Report)
iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.
See Also
Before you consider iTeos Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and iTeos Therapeutics wasn't on the list.
While iTeos Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
